Slide 1: Full Year 2024 Business Update and Financial Results
Full Year 2024 Business Update and Financial Results 27 March 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Conference call agenda
FY 2024 Business Update and Financial Results Conference call agenda Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer, Chairman of the Executive Board ANKET® & ADC Yannis Morel Chief Operating Officer Clinical Pipeline Progress Sonia Quaratino Chief Medical Officer Financial
Slide 4: Strategic Overview and Outlook
Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer Chairman of the Executive Board 4
Slide 5: 2024/2025: A Year of Strong R&D Execution
2024/2025: A Year of Strong R&D Execution IPH6501 IPH4502 Lacutamab • Trial ongoing • First in human trial initiated • FDA interactions leading to AA opportunity • IFLI collaboration • IPH45 preclinical data • Improved health-related • Preclinical publication quality of life data - ASH • TELLOMAK Ph
Slide 6: 2025: Focus on Strategic Growth Pillars
2025: Focus on 3 Strategic Growth Pillars NK-cell engagers Antibody Drug Conjugates Current Late-Stage Assets • IPH6501 (CD20) ANKET® Phase 1 • IPH4502 (Nectin-4) IND cleared, • Lacutamab positive Phase 2 data, Phase 1 FPI Jan 2025 FDA feedback on next steps, • IPH6101 (CD123) ANKET ® Phase 2 Partne
Slide 7: A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets
A Robust Pipeline of Innovative, Differentiated Proprietary & Partnered Assets Pre-Clinical Phase 1 Phase 2 Phase 3 IPH67 IPH5301 (CD73) Lacutamab (KIR3DL2) Monalizumab (NKG2A) Undisclosed, solid tumor Solid tumors CTCL Unresectable Stg III NSCLC IPH81 IPH6501 (CD20-IL2v) Lacutamab (KIR3DL2) Undiscl
Slide 8: Data across innovative oncology pipeline presented at SITC and ASH 2024
Data across innovative oncology pipeline presented at SITC and ASH 2024 ▪ Harnessing NK Cells in Cancer Therapies, Eric Vivier, CSO (Oral) ▪ Preclinical data supporting the evaluation of IPH6501 in relapsed or refractory B-NHL subtypes and post-CAR-T therapy (Poster) ▪ Preclinical data supporting IP
Slide 9: ANKET & ADC
ANKET® & ADC Yannis Morel Chief Operating Officer 9
Slide 10: Multiple ANKET programs targeting hematological malignancies and solid tumors
Multiple ANKET® programs targeting hematological malignancies and solid tumors SAR443579 progress to Ph2 in R/R AML Growing clinical pipeline New Phase 1/2 in 1L AML in combination SAR’579 / IPH6101 (CD123) Phase 1 / 2 with azacytidin + venetoclax SAR’514 / IPH6401 (BCMA) Phase 1 / 2 SAR’514/IPH6401
Slide 11: IPH6501: Innate's lead proprietary ANKET, a CD20 targeted NK cell engager
IPH6501: Innate’s lead Proprietary ANKET®, a novel CD20 targeted tetra-specific Natural Killer Cell Engager targeting B-Cells IL-2v Tumor Associated Antigen • Provides proliferation signal targeted to NK cells • CD20 TAG NKp46 binder • NK cell activating receptor • Most specific marker of human NK c
Slide 12: IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH4502: A novel and differentiated Nectin-4 DAR8 exatecan ADC Phase 1 underway Payload Exatecan, Binder a Topoisomerase I inhibitor Proprietary humanized • Active in EV/MMAE-resistant models anti-Nectin-4 Antibody • Higher Bystander Effect than EV, • High affinity leading to stronger activity i
Slide 13: IPH4502 has broad potential in Nectin-4 expressing solid tumors
ADC IPH4502 has broad potential in Nectin-4 expressing solid tumors • IPH4502 is a next-generation differentiated Nectin-4 exatecan ADC with high internalization and bystander effect • Linker’s hydrophilicity and stability translate into high ADC exposure and low release of free exatecan into cynomo
Slide 14: Pipeline Progress
Pipeline Progress Sonia Quaratino Chief Medical Officer 14
Slide 15: Proprietary key clinical pipeline progress
Proprietary key clinical pipeline progress Key clinical pipeline IPH6501 (CD20-IL2v) Phase 1 Phase 1 IPH4502 (Nectin-4) Phase 1 Lacutamab Phase 2
Slide 16: IPH6501 (CD20 ANKET): Multiple Clinical Milestones to be Delivered in Mid-term
IPH6501 (CD20 ANKET®): Multiple Clinical Milestones to be Delivered in Mid-term IPH6501 Phase 1/2 in B-NHL Safety data and preliminary Confirm activity and dose Readouts from expansion signals of activity in CD20+ optimization in CD20+ B-NHL studies in selected B-NHL B-NHL & select B-NHL subtypes su
Slide 17: IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term
ADC IPH4502 (Nectin-4 ADC): Multiple Clinical Milestones to be Delivered in Mid-term IPH4502 Phase 1 in Nectin-4 expressing tumors Start basket trial in combination with SOC Preliminary safety and activity signal in tumor types with low Readout from dose Dose FPI in Phase 1 and high Nectin-4 express
Slide 18: Lacutamab (KIR3DL2): Phase 3 ready proprietary asset with path to accelerated FDA approval
lacutamab Lacutamab (KIR3DL2): Phase 3 ready proprietary asset with path to accelerated FDA approval Lacutamab under development for treatment of First-in-class anti-KIR3DL2 humanized Cutaneous T-cell lymphomas (CTCL) and Peripheral T Cell Lymphomas (PTCL). cytotoxicity-inducing antibody Phase 2 dat
Slide 19: TELLOMAK data support lacutamab as a potential new SoC in MF & SS
lacutamab TELLOMAK data support lacutamab as a potential new SoC in MF & SS with opportunity across patient subgroups and earlier lines of therapy KIR3DL2 enriched population Expansion All comers Line Expansion ~ 1,500 patients ~3,500 patients ~5,000 patients KIR3DL2 KIR3DL2 All Comers All Comers <1
Slide 20: 2024 Financial Highlights
2024 Financial Highlights Frederic Lombard CFO 20
Slide 21: 2024 Financial highlights
2024 Financial highlights Revenue/other income from continuing Operating expenses from Cash, cash equivalents and financial operations: continuing operations: assets €20.1m €91.1m* €71.7m Runway to mid 2026 LICENSING AND COLLABORATIONS 73% expenses related to R&D €12.6m €91.1m* as of December 31, 20
Slide 22: Upcoming Catalysts and Closing Remarks
Upcoming Catalysts and Closing Remarks Jonathan Dickinson CEO 22
Slide 23: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 safety and preliminary efficacy data IPH6501 ANKET® (CD20 IL2v ANKET) | Phase 1 clinical data Proprietary IPH4502 ADC (Nectin-4 ADC) | Phase 1 safety and preliminary IPH4502 ADC (Nectin-4 ADC) | Phase 1 ongoing efficacy data
Slide 24: Key Takeaways
Key Takeaways Create value for patients and shareholders Clinical stage company with growing differentiated first-in-class pipeline • EXPAND ANKET® CLINICAL PORTFOLIO • Phase 1/2 clinical trial underway with IPH6501, a proprietary 2nd generation CD20 ANKET® in B-cell NHL • SAR’579/IPH6101 (CD123 ANK
Slide 25: Q&A
B innate pharma Q&A
Slide 26: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA